CAR-engineered cell therapies: current understandings and future perspectives

Chimeric antigen receptor (CAR)-engineered cell therapies represent a significant breakthrough in immunotherapy, initially in cancer and now expanding into diverse clinical fields. While originally developed for oncology, these platforms are increasingly being adapted for non-malignant conditions such as autoimmune disorders, infectious diseases, fibrosis, ageing-related issues, and organ transplants. This review details the evolution and diversification of CAR modalities- including CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells- as well as emerging next-generation designs. It describes the key aspects of CAR structure, signalling pathways, and manufacturing, emphasising their application in treating…

• TU
  Tabriz University of Medical Sciences
• UO
  University of Tabriz
• S
  Servier